Sun Pharma enters into license agreement with CMS for Tildrakizumab

27 Jun 2019 Evaluate

Sun Pharmaceutical Industries’ one of wholly owned subsidiaries has entered into a licensing agreement with a subsidiary of China Medical System Holdings (CMS) for the development and commercialization of Tildrakizumab, an innovative biologic product, for psoriasis and psoriatic arthritis in Greater China (including Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan).

Under terms of the license agreement, CMS will pay Sun Pharma an initial upfront payment, regulatory and sales milestone payments, and royalties on net sales, the terms of which are confidential. CMS will be responsible for development, regulatory filings and commercialization of the product in China. The initial tenure of the agreement shall be 15 years from the first commercial sale of Tildrakizumab in Greater China, and may be extended for additional 3 years’ subject to certain conditions defined in the agreement.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Sun Pharma Inds. Share Price

1727.70 7.30 (0.42%)
02-Jan-2026 14:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1727.70
Dr. Reddys Lab 1251.95
Cipla 1510.35
Zydus Lifesciences 916.05
Lupin 2109.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×